Latest News | Natco Pharma Initiates Molnupiravir Phase 3 Trials
Get latest articles and stories on Latest News at LatestLY. : Natco Pharma Limited has initiated Phase-3 clinical trials of Molnupiravir capsules in India as the first patient was dosed on Friday at Yashoda Hospitals here.
Hyderabad, May 21 (PTI): Natco Pharma Limited has initiated Phase-3 clinical trials of Molnupiravir capsules in India as the first patient was dosed on Friday at Yashoda Hospitals here.
The drug maker said in a release that pre-clinical data has shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.
Patients treated with Molnupiravir achieved response within five days of therapy, indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, it said.
"Phase-III clinical trial is initiated to evaluate the efficacy and safety of Molnupiravir Capsules in mild COVID-19 patients.
NATCOs clinical trial is planned in 32 hospitals across India," it said.
The trials will be conducted at a few hospitals in the city and Visakhapatnam in Andhra Pradesh.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)